November 24, 2016 - By Dolores Ford · 0 Comments
Amgen Inc (NASDAQ:AMGN) institutional sentiment decreased to 1.26 in 2016 Q2. Its down -0.02, from 1.28 in 2016Q1. The ratio has worsened, as 610 active investment managers increased and opened new equity positions, while 478 sold and reduced stock positions in Amgen Inc. The active investment managers in our partner’s database now own: 577.82 million shares, down from 626.39 million shares in 2016Q1. Also, the number of active investment managers holding Amgen Inc in their top 10 equity positions decreased from 74 to 71 for a decrease of 3. Sold All: 56 Reduced: 422 Increased: 533 New Position: 77.
Amgen Inc. is a biotechnology company. The company has a market cap of $106.99 billion. The Firm discovers, develops, makes and delivers various human therapeutics. It has a 14.49 P/E ratio. The Company’s business segment is human therapeutics.
The stock increased 0.48% or $0.7 on November 23, hitting $145.03. About 3.22 million shares traded hands. Amgen, Inc. (NASDAQ:AMGN) has declined 11.13% since April 22, 2016 and is downtrending. It has underperformed by 16.54% the S&P500.
Analysts await Amgen, Inc. (NASDAQ:AMGN) to report earnings on January, 26. They expect $2.77 EPS, up 6.13% or $0.16 from last year’s $2.61 per share. AMGN’s profit will be $2.04 billion for 13.09 P/E if the $2.77 EPS becomes a reality. After $3.02 actual EPS reported by Amgen, Inc. for the previous quarter, Wall Street now forecasts -8.28% negative EPS growth.
According to Zacks Investment Research, “Amgen Inc. discovers, develops and delivers innovative human therapeutics. A biotechnology pioneer, Amgen was one of the first companies to realize the new science’s promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people’s lives.”
Krensavage Asset Management Llc holds 6.9% of its portfolio in Amgen, Inc. for 125,802 shares. Merriman Wealth Management Llc owns 160,823 shares or 6.9% of their US portfolio. Moreover, Smead Capital Management Inc. has 6.46% invested in the company for 904,395 shares. The New York-based Iat Reinsurance Co Ltd. has invested 5.29% in the stock. F&V Capital Management Llc, a New York-based fund reported 43,410 shares.#img1#
Insider Transactions: Since January 1, 0001, the stock had 0 buys, and 1 insider sale for $523,758 net activity.
Ratings analysis reveals 59% of Amgen Inc.’s analysts are positive. Out of 17 Wall Street analysts rating Amgen Inc., 10 give it “Buy”, 0 “Sell” rating, while 7 recommend “Hold”. The lowest target is $160 while the high is $218. The stock’s average target of $187.39 is 29.21% above today’s ($145.03) share price. AMGN was included in 29 notes of analysts from August 3, 2015. The firm has “Market Perform” rating by Bernstein given on Wednesday, June 29. Argus Research maintained Amgen, Inc. (NASDAQ:AMGN) on Monday, February 8 with “Buy” rating. The stock of Amgen, Inc. (NASDAQ:AMGN) earned “Hold” rating by Gabelli on Friday, August 26. The rating was initiated by Raymond James with “Market Perform” on Tuesday, September 1. The firm earned “Buy” rating on Thursday, October 29 by UBS. The stock has “Buy” rating given by Mizuho on Tuesday, November 8. As per Friday, August 21, the company rating was upgraded by Vetr. The rating was initiated by Atlantic Securities with “Overweight” on Friday, December 18. The stock of Amgen, Inc. (NASDAQ:AMGN) has “Market Perform” rating given on Friday, February 5 by Leerink Swann. On Monday, September 7 the stock rating was upgraded by UBS to “Buy”.
Amgen Inc., incorporated on October 31, 1986, is a biotechnology company. The Firm discovers, develops, makes and delivers various human therapeutics. The Company’s business segment is human therapeutics. The Company’s marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as Vectibix (panitumumab), Nplate (romiplostim) and Corlanor (ivabradine). The Firm focuses its research and development on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience.
More notable recent Amgen, Inc. (NASDAQ:AMGN) news were published by: Fool.com which released: “Better Buy: Amgen Inc. vs. Johnson & Johnson” on November 08, 2016, also Fool.com with their article: “Why Amgen Inc. Shares Nose-Dived 15.4% in October” published on November 08, 2016, Fool.com published: “5 Things Amgen Inc.’s Management Wants You to Know” on October 28, 2016. More interesting news about Amgen, Inc. (NASDAQ:AMGN) were released by: Bloomberg.com and their article: “Amgen’s Repatha Unclogs Arteries in Good Sign for Future Sales” published on November 15, 2016 as well as Investorplace.com‘s news article titled: “3 Stocks to Watch on Wednesday: Amgen, Inc. (AMGN), Cisco Systems, Inc. (CSCO …” with publication date: November 17, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Dolores Ford